Fluvastatin in the first-line therapy of acute coronary syndrome: results of the multicenter, randomized, double-blind, placebo-controlled trial (the FACS-trial)

Petr Ostadal; David Alan; Jiri Vejvoda; Jiri Kukacka; Milan Macek; Petr Hajek; Martin Mates; Milan Kvapil; Jiri Kettner; Martin Wiendl; Ondrej Aschermann; Josef Slaby; Frantisek Holm; Peter Telekes; David Horak; Peter Blasko; David Zemanek; Josef Veselka; Jana Cepova

doi:10.1186/1745-6215-11-61

Fluvastatin in the first-line therapy of acute coronary syndrome: results of the multicenter, randomized, double-blind, placebo-controlled trial (the FACS-trial)

Trials ◽

10.1186/1745-6215-11-61 ◽

2010 ◽

Vol 11 (1) ◽

Cited By ~ 14

Author(s):

Petr Ostadal ◽

David Alan ◽

Jiri Vejvoda ◽

Jiri Kukacka ◽

Milan Macek ◽

...

Keyword(s):

Acute Coronary Syndrome ◽

Controlled Trial ◽

First Line ◽

Double Blind ◽

Double Blind Placebo ◽

Coronary Syndrome ◽

First Line Therapy ◽

Line Therapy

Download Full-text

A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial

Annals of Oncology ◽

10.1093/annonc/mdv027 ◽

2015 ◽

Vol 26 (5) ◽

pp. 921-927 ◽

Cited By ~ 78

Author(s):

C.S. Fuchs ◽

S. Azevedo ◽

T. Okusaka ◽

J.-L. Van Laethem ◽

L.R. Lipton ◽

...

Keyword(s):

Controlled Trial ◽

Metastatic Adenocarcinoma ◽

First Line ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

First Line Therapy ◽

Line Therapy ◽

Adenocarcinoma Of The Pancreas

Download Full-text

Rilomet-1: an International Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Trial of Rilotumumab Plus Epirubicin, Cisplatin and Capecitabine (Ecx) As First Line Therapy in Patients with Advanced Met-Positive Gastric or Gastroesophageal Junction (G/Gej) Adenocarcinoma

Annals of Oncology ◽

10.1093/annonc/mdu334.126 ◽

2014 ◽

Vol 25 ◽

pp. iv250 ◽

Cited By ~ 2

Author(s):

D. Cunningham ◽

S. Al-Batran ◽

I. Davidenko ◽

D. Ilson ◽

A.M. Murad ◽

...

Keyword(s):

Controlled Trial ◽

Gastroesophageal Junction ◽

First Line ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

First Line Therapy ◽

Line Therapy

Download Full-text

Gamma (Gemcitabine and Amg 479 for Metastatic Adenocarcinoma of the Pancreas): a Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Ganitumab Plus Gemcitabine (G) or Placebo Plus G as First-Line Therapy for Metastatic Pancreatic Cancer

Annals of Oncology ◽

10.1016/s0923-7534(20)33245-2 ◽

2012 ◽

Vol 23 ◽

pp. ix255

Author(s):

C. Fuchs ◽

S. Azevedo ◽

L. Lipton ◽

A. Carrato ◽

J. Gansert ◽

...

Keyword(s):

Pancreatic Cancer ◽

Controlled Trial ◽

Metastatic Adenocarcinoma ◽

First Line ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

First Line Therapy ◽

Line Therapy ◽

Adenocarcinoma Of The Pancreas

Download Full-text

Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO.

Journal of Clinical Oncology ◽

10.1200/jco.2008.26.15_suppl.lba1011 ◽

2008 ◽

Vol 26 (15_suppl) ◽

pp. LBA1011-LBA1011 ◽

Cited By ~ 87

Author(s):

D. Miles ◽

A. Chan ◽

G. Romieu ◽

L. Y. Dirix ◽

J. Cortes ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Phase Iii ◽

First Line ◽

Double Blind ◽

Double Blind Placebo ◽

First Line Therapy ◽

Line Therapy ◽

Phase Iii Study ◽

Locally Recurrent

Download Full-text

RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome

European Heart Journal ◽

10.1093/eurheartj/ehr334 ◽

2011 ◽

Vol 32 (20) ◽

pp. 2541-2554 ◽

Cited By ~ 126

Author(s):

Ph. Gabriel Steg ◽

Shamir R. Mehta ◽

J. Wouter Jukema ◽

Gregory Y.H. Lip ◽

C. Michael Gibson ◽

...

Keyword(s):

Acute Coronary Syndrome ◽

Controlled Trial ◽

Factor Xa ◽

Factor Xa Inhibitor ◽

The Novel ◽

Double Blind ◽

Double Blind Placebo ◽

Coronary Syndrome

Download Full-text

Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation

European Journal of Cancer ◽

10.1016/j.ejca.2016.09.024 ◽

2017 ◽

Vol 70 ◽

pp. 146-155 ◽

Cited By ~ 60

Author(s):

David Miles ◽

David Cameron ◽

Igor Bondarenko ◽

Lyudmila Manzyuk ◽

Juan Carlos Alcedo ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Phase Iii ◽

First Line ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo ◽

First Line Therapy ◽

Line Therapy ◽

Biomarker Evaluation

Download Full-text

Randomised, Double-Blind, Placebo-Controlled Trial of Ivabradine in Patients with Acute Coronary Syndrome: Effects of the I f Current Inhibitor Ivabradine on Reduction of Inflammation Markers in Patients with Acute Coronary Syndrome—RIVIERA Trial Study Design and Rationale

Cardiovascular Drugs and Therapy ◽

10.1007/s10557-009-6164-9 ◽

2009 ◽

Vol 23 (3) ◽

pp. 243-247 ◽

Cited By ~ 12

Author(s):

Alberto Dominguez-Rodriguez ◽

Sima Samimi Fard ◽

Pedro Abreu-Gonzalez ◽

Francisco Bosa-Ojeda ◽

Luciano Consuegra-Sanchez ◽

...

Keyword(s):

Acute Coronary Syndrome ◽

Study Design ◽

Controlled Trial ◽

Inflammation Markers ◽

Double Blind ◽

Double Blind Placebo ◽

Coronary Syndrome

Download Full-text

Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study

Yearbook of Oncology ◽

10.1016/j.yonc.2012.05.013 ◽

2012 ◽

Vol 2012 ◽

pp. 138-139 ◽

Cited By ~ 1

Author(s):

E.G. Chiorean

Keyword(s):

Gastric Cancer ◽

Advanced Gastric Cancer ◽

Phase Iii ◽

First Line ◽

Double Blind ◽

Double Blind Placebo ◽

First Line Therapy ◽

Line Therapy ◽

Phase Iii Study

Download Full-text

Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomised, double-blind, placebo-controlled trial

The Lancet ◽

10.1016/s0140-6736(08)60763-1 ◽

2008 ◽

Vol 371 (9626) ◽

pp. 1761-1768 ◽

Cited By ~ 132

Author(s):

Jean-Claude Tardif ◽

John JV McMurray ◽

Eric Klug ◽

Robert Small ◽

Jennifer Schumi ◽

...

Keyword(s):

Acute Coronary Syndrome ◽

Controlled Trial ◽

Double Blind ◽

Double Blind Placebo ◽

Coronary Syndrome

Download Full-text

Abstract S6-01: Phase 3, randomized, double-blind, placebo-controlled multicenter trial of daily everolimus plus weekly trastuzumab and paclitaxel as first-line therapy in women with HER2+ advanced breast cancer: BOLERO-1

10.1158/1538-7445.sabcs14-s6-01 ◽

2015 ◽

Cited By ~ 4

Author(s):

Sara A Hurvitz ◽

Fabrice Andre ◽

Zefei Jiang ◽

Zhimin Shao ◽

Silvia P Neciosup ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Multicenter Trial ◽

Advanced Breast ◽

First Line ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

First Line Therapy ◽

Line Therapy

Download Full-text